Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Could become the gold standard once approved
A Phase I/II trial published in the Journal of Clinical Endocrinology & Metabolism (2006) studied CJC-1295 with DAC in healthy adults aged 21-61: Single doses of 30, 60, or 125 g/kg produced dose-dependent increases in GH and IGF-1 Mean GH levels increased 2-10 fold for up to 6 days after a single injection IGF-1 levels increased 1.5-3 fold and remained elevated for 9-11 days After 2-3 weekly doses, steady-state IGF-1 elevation was achieved The most common adverse events were injection site reactions, headache, and diarrhea No serious adverse events were reported in the study timeframe Important Context: ConjuChem's clinical development program for CJC-1295 with DAC was discontinued after a subject death in a subsequent trial
BALLOON CELL NEVUS This peculiar change can be found in 1.7% of all melanocytic proliferations (74,75) and can be seen in almost any type of melanocytic proliferation including intranodal nevic nests (76)
The TRAVERSE triala large, well-regarded study on TRTdidnt find a significant benefit in preventing worsening insulin resistance in men with prediabetes
US$ 24.51
US$ 29.88
US$ 27.47
